NX210c drug candidate peptide strengthens mouse and human blood-brain barriers
In summary, we have gathered preclinical data showing the capacity of NX210c to strengthen BBB integrity. Through this property, NX210c holds great promises of being a disease-modifying treatment for several neurological disorders with high unmet medical needs.
Authors
- Damir Janigro (ORCID: https://orcid.org/0000-0003-2165-5826)
- Matthew E. Campbell (ORCID: https://orcid.org/0000-0003-3325-240X)
- Yann Godfrin
- Gwen Fewell
- Sighild Lemarchant (ORCID: https://orcid.org/0000-0001-8671-9099)
- Chris Greene (ORCID: https://orcid.org/0000-0003-4192-9433)
- Nicolas Rebergue
Institutions
- Synlab Czech (Czechia) (CZ)
- Trinity College Dublin (IE)
- Setaram Instrumentation (France) (FR)
- Erytech Pharma (France) (FR)
- Hochtief (Czechia) (CZ)
Publication Details
- Journal
- Fluids and Barriers of the CNS
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12987-024-00577-x
- Citations
- 6
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.48
Funders
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Université Claude Bernard Lyon 1
- Région Auvergne-Rhône-Alpes